RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing ...

Scientists have created a more efficient and controlled way to produce lab-grown inner ear hair cells than current methods ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

British researchers who tested almost 1,000 patients with the allergy, found almost 90 per cent could actually safely use the drug.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as ...

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...